4-HO-DiPT Stats & Data

4-HO-DiPT was first described in the scientific literature in 1977, with its synthesis published by chemist David B. Repke. Two decades later, Alexander Shulgin investigated the substance's effects in humans and characterized it in his 1997 book TiHKAL ("Tryptamines I Have Known and Loved"). Shulgin noted that 4-HO-DiPT possessed an unusual combination of properties among psychedelics, including rapid onset (becoming apparent approximately 15 minutes after ingestion), considerable intensity at relatively low doses (with 20 milligrams capable of producing a transcendent peak experience), brief overall duration (typically 2-3 hours), and pronounced dose sensitivity. The compound was subsequently encountered as a novel designer drug by 2005 and has since circulated on the online research chemical market, though it remains relatively uncommon. Today, 4-HO-DiPT is used for both recreational and entheogenic purposes, though it has a limited history of human use. In the 2020s, pharmaceutical interest emerged with the development of luvesilocin (also known as RE-104, FT-104, or 4-GO-DiPT), a prodrug of 4-HO-DiPT that has entered phase 2 clinical trials for the treatment of psychiatric conditions including postpartum depression and treatment-resistant depression.

The toxicity and long-term health effects of recreational 4-HO-DiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-DiPT is a research chemical with very little history of human usage. Anecdotal reports from those who have tried 4-HO-DiPT suggests that there are no negative health effects attributed to simply trying it by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Effects aggregated from 32 experience reports (32 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Also reported in combinations. In the 21 4-HO-DiPT reports where another drug was taken too, 1 (4.8%) mentions hospital, emergency services or an overdose, 1 (4.8%) a seizure and 0 (0.0%) psychosis. In the 32 single-substance reports: 6.2%, 0.0% and 3.1%. These are not in the figures above: they cannot be put down to 4-HO-DiPT alone, and a mention is not always something that happened to the writer.

How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

Not drawn, too few reports (a dose tier needs 20): Oral Strong (n=11). Why 20?

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

From 65 of 70 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 53 reports filed under 4-HO-DiPT; whiskers are 95% intervals

Most common forms and preparations, as a share of the 39 reports that give one; whiskers are 95% intervals

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 43 reports